TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A phase II trial involving 18 breast cancer survivors found that participants who completed eight weeks of oxaloacetate supplementation reported improvements in cognitive symptoms and fatigue. The study also recorded gains on some cognitive tests, but its small size and lack of confirmation in larger studies mean the results are preliminary.
A small phase II clinical trial led by researchers at UCLA Health’s Jonsson Comprehensive Cancer Center found that breast cancer survivors who took oxaloacetate twice daily for eight weeks reported improvements in brain fog and fatigue. The results, published in JCO Oncology Advances, are early evidence—not proof that the supplement works—and researchers say larger studies are needed.
The trial enrolled 18 women diagnosed with early-stage breast cancer one to five years earlier, all of whom reported substantial cognitive difficulties at the start. Sixteen completed the eight-week study. Participants took 500 milligrams twice a day, while researchers tracked symptoms through questionnaires and tests of memory, attention, processing speed and executive function. The latter includes skills such as planning, staying focused and managing tasks.
All 16 participants who completed the study reported improvement in cognitive symptoms. On the trial’s main measure of perceived cognitive impairment, the group’s average score rose from 29.1 before supplementation to 55.5 after eight weeks, a level the report says fell in the range considered normal rather than impaired. Improvement was apparent by week four and generally increased over the treatment period, according to the study report.
Participants also reported less fatigue and better physical functioning. Researchers observed improvement on tests of processing speed and executive function as well. Oxaloacetate was generally well tolerated during the trial; reported side effects most often involved the digestive system, including indigestion. The available report does not establish how often each side effect occurred or whether the improvements persisted after participants stopped taking the supplement.
What the Results Could Mean for Survivors
Cognitive problems after cancer treatment can affect routine activities, including concentrating at work, remembering information and organizing daily tasks. The study points to a possible intervention for people who continue to experience these symptoms, at a time when the report says effective treatment options remain limited. Its relevance is heightened by the combination of reported symptom changes and improvement on some standardized tests, rather than relying on participants’ impressions alone.
But the findings do not show that oxaloacetate will help all survivors, or that it is ready to be recommended as treatment. The trial was small, and the reported changes need testing in larger, controlled studies. Readers should treat the supplement as under investigation, not as an established remedy, and discuss supplement use with a health professional—particularly while receiving cancer treatment or taking other medication.
Products Worth Considering
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Hyperice Hypervolt 3 Pro Percussion Massage Gun with Heated Head and Carry Case
As an affiliate, we earn on qualifying purchases.
Survivors may describe memory, concentration and thinking difficulties as “chemo brain,” but the term can give an incomplete account of possible causes. The ScienceDaily report says cognitive impairment may be associated with the cancer itself, chemotherapy, endocrine therapy, inflammation and hormonal changes, among other biological and behavioral influences. Many trial participants were still receiving endocrine therapy, and most had undergone chemotherapy.
The UCLA researchers focused on oxaloacetate because it is a molecule already found in the body and plays a role in cellular energy production and the regulation of glutamate, a chemical involved in communication between nerve cells. The researchers’ rationale was that inflammation and disruptions to brain-cell energy processes or glutamate signaling might contribute to cognitive symptoms. The trial tested whether supplementation was associated with changes in symptoms; it does not, by itself, establish that this proposed mechanism explains the results.
“Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it.”
— Dr. Patricia Ganz, the study’s first author and a professor at UCLA
What the Small Trial Cannot Show
The trial included only 18 participants, and 16 completed the full eight weeks. The supplied report does not describe a placebo or comparison group, so it is not possible from these results to determine how much of the reported change was specifically caused by oxaloacetate rather than other factors. It also remains unclear whether the improvements last beyond the supplementation period or apply to survivors with different cancer histories and symptom levels.
The study offers no basis for concluding that oxaloacetate prevents or reverses brain changes, or for recommending a dose for general use. More information is needed about the frequency and severity of side effects, possible interactions, and outcomes in larger groups. The reported improvements should be read as early findings, not a confirmed treatment effect.
Larger Studies Must Test the Findings
The researchers say larger studies are needed to confirm whether oxaloacetate improves cognitive symptoms and fatigue after breast cancer treatment. Future research would need to clarify the size and duration of any benefit, compare outcomes against an appropriate control group, and examine safety over longer periods. The source report does not provide a timetable for a follow-up trial.
Until additional evidence is available, survivors experiencing persistent brain fog can raise symptoms and supplement questions with their oncology team or another qualified health professional. The next meaningful milestone is independent confirmation in a larger study; no such result or regulatory decision is reported here.
Key Questions
What is oxaloacetate?
Oxaloacetate is a molecule that occurs naturally in the body and participates in cellular energy production. The UCLA-led trial tested it as a supplement for cognitive symptoms and fatigue among breast cancer survivors.
How many people took part in the trial?
The phase II trial enrolled 18 women; 16 completed the eight-week supplementation period. All had substantial cognitive difficulties when they entered the study.
Did the study prove that oxaloacetate clears brain fog?
No. Participants who completed the trial reported improvement, and some cognitive test results also improved, but the study was small and preliminary. Larger studies are needed to confirm whether the supplement caused the changes and whether they last.
What dose did participants take, and were side effects reported?
Participants took 500 milligrams twice daily for eight weeks. The supplement was generally well tolerated in the study, with digestive complaints such as indigestion among the reported side effects. Anyone considering a supplement should discuss it with a health professional, especially during cancer care or when taking other medicines.
Source: sciencedaily.com
